Survival Outcomes of Lung Cancer
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHunan Province Tumor Hospital
About this trial
This is a prospective study to analyze the survival outcomes of different groups about lung cancer patients.
Eligibility criteria
Qualifiers
Understand the requirements and contents of the clinical trial .
Age ≥ 18 years.
Histopathology or cytology confirmed lung cancer
ECOG <=2.
Disqualifiers
Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity. Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose.
Ongoing (or inability to discontinue) possibly potent CYP1A2, CYP3A inhibitor (1 week), or inducer (2 weeks) drug therapy or herbal supplements within 1-2 weeks prior to the first dose.
Presence of spinal cord compression or meningeal metastasis.
History of other malignant tumors within 2 years.
Trial design
Treatments tested in this trial
- Treatment
Treatment groups
20,000 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov